What Can You Expect at the Flagship CGT Analytical Development Summit?
Landmark approvals, growing momentum behind in vivo cell therapies, and new FDA flexibility are changing the sentiment around cell and gene therapies this year. However, as new technologies emerge the standard for analytical data packages increases with it. Now, the biggest challenge for biopharma becomes working smarter to generate the right amount of potency, quality, safety, and sterility data to assure clinical progress and commercial approvals while keeping down manufacturing costs to protect long term ROI.
This year, the 8th Cell & Gene Therapy Analytical Development Summit combines the best of both worlds in many ways: strategic and technical presentations, opportunities for informative presentations and interactive networking, and for the first time, both cell and gene therapies represented under one roof.
Join experts from Bristol Myers Squibb, Novartis, Vertex Pharmaceuticals, Sarepta Therapeutics, AskBio, Sanofi, and more are tackling analytical development for the wave of cell and gene therapies.
Unmissable Event Highlights
Build Potency Assays That Stand Up to Validation
Learn how Novartis, Voyager Therapeutics, ProKidney, and Stanford Laboratory for Cell and Gene Medicine are improving potency assay robustness, qualification strategies, and decision-making across development and QC.
Prepare Your Analytics for Commercial Success
Discover how Bristol Myers Squibb and Vertex Pharmaceuticals are evolving analytical control strategies, specifications, and QC frameworks from early development through BLA preparation.
Unlock Deeper Product Characterization with Next-Generation Analytics
Explore how leaders from AskBio, Sarepta Therapeutics, Astellas, and Apertura Gene Therapy are applying NGS, advanced characterization techniques, and novel analytical approaches to improve product understanding.
Leverage AI, Single-Cell Analytics & Emerging Technologies
Gain insight into how GC Therapeutics and Expression Therapeutics are using AI, modeling, and single-cell datasets to strengthen comparability studies, improve assay performance, and accelerate decision-making.
Improve Assay Transferability & QC Readiness
Learn how Sanofi, Alexion Pharmaceuticals, and other industry leaders are reducing redevelopment, streamlining method transfer, and preparing assays for successful GMP and QC implementation.
Explore the Full Event Guide
- Interactive Workshops on Flow Cytometry, NGS & Potency Assay Development Challenges
- Exclusive Case Studies on Potency, Comparability & Analytical Control Across Cell & Gene Therapy
- Expert-Led Discussions on AI, Single-Cell Analytics & Next-Generation Analytical Technologies
- Practical Strategies for Method Transfer, QC Readiness & Commercialization Success
- Unrivaled Networking with Analytical Development, QC, CMC & Regulatory Leaders from Across the Industry
Attending Companies Included
Explore the Agenda
Discover practical case studies, interactive workshops, and expert-led discussions tackling today's biggest cell & gene therapy analytical development challenges.
Partner With Us
Connect with analytical development, QC, and CMC decision-makers actively evaluating technologies, services, and outsourcing partners.
Join Industry Leaders
Benchmark your approach against the scientists and analytical leaders shaping potency, product characterization, analytical control, and regulatory readiness across cell & gene therapy